Epidemiology of lower extremity artery disease.
[Epidemiology of lower extremity artery disease]. Presse Med. 2018 Feb 12;: Authors: Aboyans V, Sevestre MA, Désormais I, Lacroix P, Fowkes G, Criqui MH Abstract It is estimated that more than 200 million individuals are affected by lower extremity artery disease (LEAD) worldwide. This prevalence has increased between 2000 and 2010 by 25%, especially in low/middle income countries. In France, about one million people are affected by this condition. Almost two-thirds of patients with LEAD are asymptomatic. This explains the interest of the measurement of the ankle-brachial index (ABI), an objective and harmless diagnostic tool. An ABI≤0.90 is considered as diagnostic for LEAD. The detection of symptomatic LEAD requires standardized questionnaires identifying intermittent claudication. Epidemiological studies on chronic limb-threatening ischemia (CLTI) - the most severe presentation of the disease - are scarce: the prevalence is estimated around 0.5-2.0% after the age of 40, mostly affecting elderly people. Similar to other atherosclerotic diseases, the risk factors are multiple (genetic factors, traditional risk factors, metabolic and inflammatory factors, socioeconomic factors), with different weighs of association as compared to coronary artery diseases. Due to their high prevalence and strength of association, cigarette smoking and hypertension are the most frequent purveyors of this disease in population. Diabetes mellitus is a str...
More than a third of patients with diabetes don't take their drugs as prescribed, sometimes because of cost concerns.
Among women with metastatic breast cancer, use of an investigational oral form of paclitaxel yielded a higher overall response rate than the IV form, but administration was unique and time-consuming.Medscape Medical News
Publication date: 14–20 December 2019Source: The Lancet, Volume 394, Issue 10215Author(s): Basu Dev Pandey, Anthony Costello
Publication date: 14–20 December 2019Source: The Lancet, Volume 394, Issue 10215Author(s): Mohammed A Mamun, Jannatul Mawa Misti, Mark D Griffiths, David Gozal
Publication date: Available online 12 December 2019Source: The LancetAuthor(s): Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Simon Cawthorn, Robert E Mansel, Sibylle Loibl, Bernardo Bonanni, D Gareth Evans, Anthony Howell, IBIS-II investigatorsSummaryBackgroundTwo large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II]). Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo...
Three medical stories that we didn't cover, explained.Medscape
ConclusionThe present study reports a variant subgroup GII-a PEDV HM2017 strain in China and characterize its pathogenicity. PEDV strain HM2017 of subgroup GII-a presents a promising vaccine candidate for the control of PED outbreaks in China.
ConclusionThis study shows that NHs within our region are an important reservoir of ESBLE, whereas no residents were CPE carrier. ESBLE control in NHs should focus on antibiotic stewardship and excreta management policies.
Publication date: Available online 13 December 2019Source: Journal of Hospital InfectionAuthor(s): Helena C. Maltezou, Xanthi Dedoukou, Elpida Pavi, Maria Thoeodoridou, Kostas AthanasakisSummaryMeasles represents an occupational risk for healthcare personnel (HCP). A total of 117 cases of measles among HCP were notified in Greece during 2017-2018. We were able to contact 46 of them. Most of those contacted had a serious clinical course with complications, necessitating hospitalization in 67% of cases. All HCP reported absenteeism, for a mean duration of 21.2 working days (range: 3-60 days); 54.3% of HCP reported being at w...
ConclusionsMHSCC seems to show a better overall survival compared to OSCC of other locations and is less likely to develop regional and distant metastasis; END might not be necessary in early stage tumors.